Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 1/20 | 0.40 |
| ▸ | CA1 | P00915 | 1/20 | 0.40 |
| ▸ | CA2 | P00918 | 1/20 | 0.40 |
| ▸ | CA3 | P07451 | 1/20 | 0.40 |
| ▸ | CA4 | P22748 | 1/20 | 0.40 |
| ▸ | CA6 | P23280 | 1/20 | 0.40 |
| ▸ | CA5A | P35218 | 1/20 | 0.40 |
| ▸ | CA7 | P43166 | 1/20 | 0.40 |
| ▸ | CA9 | Q16790 | 1/20 | 0.40 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.40 |
| ▸ | CA5B | Q9Y2D0 | 1/20 | 0.40 |
| ▸ | KAT6A | Q92794 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.39 |
| ▸ | CHEK2 | O96017 | 1/20 | 0.38 |
| ▸ | PARP1 | P09874 | 1/20 | 0.37 |
| ▸ | PHGDH | O43175 | 1/20 | 0.37 |
| ▸ | KDM4A | O75164 | 1/20 | 0.36 |
| ▸ | KDM4B | O94953 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28282439 | 0.84 | CA2 (0.52) | CA12CA1CA2CA3CA4 | |
| SCHEMBL9842300 | 0.84 | KAT6A (0.42) | CA12CA1CA2CA3CA4 | |
| SCHEMBL27732241 | 0.81 | KAT6A (0.49) | KAT6AALDH1A1HSD17B10TDP1PARP1 | |
| SCHEMBL28295968 | 0.80 | KDM4E (0.47) | CA12CA1CA2CA3CA4 | |
| SCHEMBL679357 | 0.76 | METAP2 (0.46) | ALDH1A1HSD17B10 | |
| SCHEMBL3245236 | 0.76 | CHEK2 (0.41) | KAT6AALDH1A1TDP1CHEK2PARP1 | |
| SCHEMBL6512842 | 0.74 | RAB9A (0.47) | ALDH1A1TDP1CHEK2PARP1KDM4A | |
| SCHEMBL30589692 | 0.73 | PIK3CD (0.47) | ALDH1A1CHEK2PARP1KDM4AKDM4B | |
| SCHEMBL6756644 | 0.73 | MAPT (0.53) | ALDH1A1TDP1 | |
| SCHEMBL18725070 | 0.72 | TSHR (0.39) | KAT6AALDH1A1TDP1CHEK2PARP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7728002-B2 | Use of pyrrolopyridine compounds for activating PPAR receptors and treatment of conditions involving such receptors | LABORATOIRES FOURNIER S.A. (FR) | 2010-06-01 | — | — | US | disclosed |
| US-20090239856-A1 | Use of Pyrrolopyridine Compounds for Activating PPAR Receptors and Treatment of Conditions Involving Such Receptors | LABORATOIRES FOURNIER S.A. (FR) | 2009-09-24 | — | — | US | disclosed |
| US-7557122-B2 | Pyrrolopyridine compounds, method of making them and uses thereof | LABORATOIRES FOURNIER S.A. (FR) | 2009-07-07 | — | — | US | disclosed |
| US-20080200495-A1 | Pyrrolopyridine Compounds, Method of Making Them and Uses Thereof | LABORATOIRES FOURNIER S.A. (FR) | 2008-08-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090239856-A1 | Use of Pyrrolopyridine Compounds for Activating PPAR Receptors and Treatment of Conditions Involving Such Receptors | PPARD, PPARA, PPARG | CA12 4861/4885CA1 4506/4885CA2 3289/4885 |
| US-20080200495-A1 | Pyrrolopyridine Compounds, Method of Making Them and Uses Thereof | LIPG, PCSK9, PNLIP | CA12 4821/4885CA1 4518/4885CA2 3468/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.